Evaluation of the efficacy and safety of either or both mirabegron and silodosin, as a medical expulsive therapy for distal ureteric stones

Objective To evaluate efficacy and safety of either or both silodosin and mirabegron as MET for distal ureteric stones ≤ 10 mm.

Patients and methods This study enrolled a total of 105 patients, aged between 20 and 56 years, diagnosed by single radiopaque distal ureteral stone measuring ≤ 10 mm.

The recruitment period spanned from May 2020 to December 2021.

The patients were randomly divided into three groups, with each group consisting of 35 participants.

Group A received a once-daily dose of 8 mg of silodosin, group B received a once-daily dose of 50 mg of mirabegron, and group C received a combination of both medications.

Treatment was administered to all patients until the stone was expelled or for a maximum duration of four weeks.

The stone-free rate was determined by analyzing KUB films with or without ultrasonography.

Results The rate of stone expulsion was significantly higher in group C compared to groups A and B (P = 0.04 and P = 0.004, respectively).

The mean (standard deviation) time for stone expulsion in groups A, B, and C was 14 ± 2.3 days, 11 ± 3.1 days, and 7 ± 2.2 days, respectively.

Group C demonstrated a significantly shorter stone expulsion time compared to groups A and B (P = 0.001 and P = 0.04, respectively).

The frequency of renal colic in group C was significantly lower than that in groups A and B, resulting in a reduced requirement for analgesics (P < 0.05).

Anejaculation occurred at a significantly higher rate in the silodosin group (73.9%) and combination group (84%) compared to the mirabegron group (P < 0.05).

Conclusions The findings of this study suggest that both silodosin and mirabegron are effective treatments for the expulsion of lower ureteric stones.

Furthermore, the combination of these medications leads to an increased rate of stone expulsion and a reduced duration of expulsion.